Easterly Investment Partners’s Co-Diagnostics CODX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-4,140
Closed -$313K 193
2022
Q4
$313K Sell
4,140
-166
-4% -$15.5K 0.03% 168
2022
Q3
$415K Hold
4,306
0.04% 160
2022
Q2
$725K Sell
4,306
-434
-9% -$66K 0.06% 144
2022
Q1
$879K Sell
4,740
-500
-10% -$104K 0.07% 142
2021
Q4
$1.4M Sell
5,240
-166
-3% -$43.5K 0.1% 127
2021
Q3
$1.58M Buy
+5,406
New +$1.58M 0.11% 120

Other funds holding CODX

Easterly Investment Partners's CODX Position: Q1 2023 in Review

Easterly Investment Partners sold out of Co-Diagnostics (CODX) in Q1 2023, closing a stake of 4,140 shares — an estimated $313K sold.

Easterly Investment Partners first reported a position in CODX in Q3 2021 and held it in 6 quarters. The position peaked at $1.58M in Q3 2021. 51 funds tracked by Wall St. Rank hold CODX as of Q1 2023.

  • Easterly Investment Partners reported no remaining Co-Diagnostics position as of Q1 2023 after selling out during the quarter.
  • Easterly Investment Partners sold 4,140 Co-Diagnostics shares in Q1 2023, an estimated $313K.
  • Easterly Investment Partners first reported a position in Co-Diagnostics in Q3 2021 and held it in 6 quarters.
  • Easterly Investment Partners's Co-Diagnostics position peaked at $1.58M in Q3 2021.
  • 51 funds tracked by Wall St. Rank held Co-Diagnostics as of Q1 2023.

Based on Easterly Investment Partners's 13F filing for Q1 2023, filed 2 May 2023.